Marks LS - Search Results

1

The prostate health index selectively identifies clinically significant prostate cancer.

Loeb S, Sanda MG, Broyles DL, Shin SS, Bangma CH, Wei JT, Partin AW, Klee GG, Slawin KM, Marks LS, van Schaik RH, Chan DW, Sokoll LJ, Cruz AB, Mizrahi IA, Catalona WJ. Loeb S, et al. Among authors: marks ls. J Urol. 2015 Apr;193(4):1163-9. doi: 10.1016/j.juro.2014.10.121. Epub 2014 Nov 15. J Urol. 2015. PMID: 25463993 Free PMC article.

2

Morphometry of the prostate: I. Distribution of tissue components in hyperplastic glands.

Marks LS, Treiger B, Dorey FJ, Fu YS, deKernion JB. Marks LS, et al. Urology. 1994 Oct;44(4):486-92. doi: 10.1016/s0090-4295(94)80044-8. Urology. 1994. PMID: 7524234

3

Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia.

Marks LS, Dorey FJ, Rhodes T, Shery ED, Rittenhouse H, Partin AW, deKernion JB. Marks LS, et al. J Urol. 1996 Sep;156(3):1035-9. J Urol. 1996. PMID: 8709302

4

Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia.

Marks LS, Partin AW, Gormley GJ, Dorey FJ, Shery ED, Garris JB, Subong EN, Stoner E, deKernion JB. Marks LS, et al. J Urol. 1997 Jun;157(6):2171-8. J Urol. 1997. PMID: 9146609 Clinical Trial.

5

Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia.

Pannek J, Marks LS, Pearson JD, Rittenhouse HG, Chan DW, Shery ED, Gormley GJ, Subong EN, Kelley CA, Stoner E, Partin AW. Pannek J, et al. Among authors: marks ls. J Urol. 1998 Feb;159(2):449-53. doi: 10.1016/s0022-5347(01)63946-6. J Urol. 1998. PMID: 9649261 Clinical Trial.

6

Treatment of erectile dysfunction with sildenafil.

Marks LS, Duda C, Dorey FJ, Macairan ML, Santos PB. Marks LS, et al. Urology. 1999 Jan;53(1):19-24. doi: 10.1016/s0090-4295(98)00525-1. Urology. 1999. PMID: 9886582 Clinical Trial.

7

Long-term effects of finasteride on prostate tissue composition.

Marks LS, Partin AW, Dorey FJ, Gormley GJ, Epstein JI, Garris JB, Macairan ML, Shery ED, Santos PB, Stoner E, deKernion JB. Marks LS, et al. Urology. 1999 Mar;53(3):574-80. Urology. 1999. PMID: 10096387 Clinical Trial.

8

"BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia.

Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Wolfert RL, Marks LS, Song W, Wheeler TM, Slawin KM. Mikolajczyk SD, et al. Among authors: marks ls. Urology. 2000 Jan;55(1):41-5. doi: 10.1016/s0090-4295(99)00372-6. Urology. 2000. PMID: 10654892

9

A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue.

Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Marks LS, Song W, Wheeler TM, Slawin KM. Mikolajczyk SD, et al. Among authors: marks ls. Cancer Res. 2000 Feb 1;60(3):756-9. Cancer Res. 2000. PMID: 10676664

10

Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia.

Marks LS, Partin AW, Epstein JI, Tyler VE, Simon I, Macairan ML, Chan TL, Dorey FJ, Garris JB, Veltri RW, Santos PB, Stonebrook KA, deKernion JB. Marks LS, et al. J Urol. 2000 May;163(5):1451-6. J Urol. 2000. PMID: 10751856 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

222 results

Search Page

Filters